Will Insulin Cost More in 2026? Tariff Impact on Lantus, NovoLog & Alternatives
The 2026 drug tariff hits imported insulin like Lantus and NovoLog. See which insulins are affected, which are exempt, and how the $35 Medicare cap protects you.
Insulin is one of the most essential — and emotionally charged — medications in America. Millions depend on it daily. With the 100% pharmaceutical tariff effective July 31, 2026, many patients are asking: will insulin cost more? The answer depends on three things: which insulin you use, where it's manufactured, and what type of insurance you have. Here's the complete breakdown.
The Good News First: Medicare $35 Cap
If you're on Medicare Part D, your insulin copay is capped at $35/month by federal law (Inflation Reduction Act). This cap applies regardless of the tariff. Medicare beneficiaries are protected.
Which Insulins Are Affected by the Tariff?
| Insulin | Manufacturer | Country | Tariff Status |
|---|---|---|---|
| Lantus | Sanofi | France | Affected |
| Toujeo | Sanofi | France | Affected |
| Basaglar | Eli Lilly | USA | Exempt |
| Tresiba | Novo Nordisk | Denmark | Affected |
| Levemir | Novo Nordisk | Denmark | Affected |
| Humalog | Eli Lilly | USA/Puerto Rico | Exempt |
| Admelog | Sanofi | USA | Exempt |
| NovoLog | Novo Nordisk | Denmark | Affected |
| Fiasp | Novo Nordisk | Denmark | Affected |
| Apidra | Sanofi | Germany | Affected |
| Lyumjev | Eli Lilly | USA | Exempt |
| Humulin | Eli Lilly | USA | Exempt |
| Semglee (biosimilar) | Mylan/Biocon | India | Exempt (biosimilar) |
| Rezvoglar (biosimilar) | Eli Lilly | USA | Exempt (biosimilar + US-made) |
Key pattern: Eli Lilly makes most of its insulins in the US or Puerto Rico. Novo Nordisk and Sanofi make their insulins primarily in Europe. US-made Lilly insulins are exempt.
Specific Impact by Insulin
Lantus (insulin glargine) — AFFECTED
- Manufacturer: Sanofi (France)
- Current retail: ~$285/month (one 10mL vial)
- Current Medicare copay: $35 (capped)
- Projected retail after tariff (likely): ~$428/month
- Projected retail after tariff (worst): ~$570/month
- Medicare copay: unchanged at $35
Best alternative: Semglee or Rezvoglar (biosimilar versions of insulin glargine) — both exempt.
NovoLog (insulin aspart) — AFFECTED
- Manufacturer: Novo Nordisk (Denmark)
- Current retail: ~$340/month
- Current Medicare copay: $35 (capped)
- Projected retail after tariff (likely): ~$510/month
- Projected retail after tariff (worst): ~$680/month
- Medicare copay: unchanged at $35
Best alternative: Admelog (insulin lispro by Sanofi, US-made) or Humalog (insulin lispro by Lilly, US-made).
Tresiba (insulin degludec) — AFFECTED
- Manufacturer: Novo Nordisk (Denmark)
- Current retail: ~$450/month
- Projected retail after tariff (likely): ~$675/month
- Medicare copay: unchanged at $35
Best alternative: Basaglar (insulin glargine biosimilar by Lilly, US-made) for long-acting basal coverage.
Humalog (insulin lispro) — EXEMPT
Made by Eli Lilly in Indianapolis. No tariff impact. Current retail ~$275/month remains stable.
Humulin (insulin human) — EXEMPT
Made by Eli Lilly in Indianapolis. No tariff impact. Humulin R (regular) and Humulin N (NPH) both exempt. Often the cheapest insulin option.
Coverage Scenarios: What You'll Actually Pay
Scenario A: Medicare Part D Enrollee
$35/month cap applies. Your cost does not change due to the tariff. Monthly insulin cost remains $35 regardless of which insulin you use, as long as it's covered by your plan.
Scenario B: Commercial Insurance (Tier 2 preferred brand)
| Timeline | Lantus Copay | Humalog Copay | NovoLog Copay |
|---|---|---|---|
| April 2026 | $35-50 | $35-50 | $35-50 |
| Aug 2026 (likely) | $50-75 | $35-50 (unchanged) | $50-75 |
| Aug 2026 (worst) | $75-150 | $35-50 (unchanged) | $75-150 |
Insurance may shift Lantus and NovoLog to higher tiers; US-made insulins may become preferred.
Scenario C: Uninsured / Cash-Pay
You bear the full impact. For a uninsured Type 1 diabetic using Lantus + NovoLog (common combination):
| Timeline | Monthly Cost | Annual Cost |
|---|---|---|
| April 2026 | $625 ($285 + $340) | $7,500 |
| Aug 2026 (likely) | $938 ($428 + $510) | $11,256 |
| Annual increase | +$313/month | +$3,756/year |
Switching to US-made alternatives (Basaglar + Humalog or Admelog) keeps you at pre-tariff pricing.
Biosimilar Insulins: Exempt and Cheaper
Biosimilar insulins are exempt from the tariff and typically 30-65% cheaper than the reference brand:
| Biosimilar | Reference Drug | Typical Price | Exempt? |
|---|---|---|---|
| Semglee | Lantus | ~$100-150/month | Yes (biosimilar) |
| Rezvoglar | Lantus | ~$140/month | Yes (biosimilar + US-made) |
| Basaglar | Lantus | ~$275/month | Yes (US-made) |
Semglee is interchangeable with Lantus, meaning your pharmacist can substitute it without a new prescription (in most states).
How to Switch to Exempt Insulin
Step 1: Identify Your Current Insulin
Check the pharmacy label. It tells you the brand name, generic name, manufacturer, and often the country of manufacture.
Step 2: Talk to Your Doctor
Switching insulin is clinically more sensitive than switching some other drugs. Key considerations:
- Long-acting ≈ long-acting: Lantus → Basaglar is generally straightforward (same molecule)
- Rapid-acting ≈ rapid-acting: NovoLog → Humalog is typically a 1:1 unit substitution
- Dose may need adjustment: Some patients need 10-20% dose adjustment when switching
- Insurance formulary: Your insurer may prefer certain brands
Step 3: Get Insurance Approval
Most plans don't require prior authorization for commonly used insulins, but some do for biosimilars. Check with your insurance.
Step 4: Monitor Blood Glucose
After switching, monitor for 2-4 weeks:
- Check fasting glucose daily
- Check postprandial glucose after meals
- Watch for hypoglycemia or sustained hyperglycemia
- A1C at 3 months
Manufacturer Assistance Programs
Sanofi Patient Connection
For Lantus, Toujeo, Apidra:
- Income-based eligibility
- Free insulin for qualifying uninsured patients
- Apply at sanofipatientconnection.com
Eli Lilly Insulin Value Program
- $35/month cap for commercial, uninsured, or cash-pay patients
- No income requirement
- Apply at insulinaffordability.com
Novo Nordisk PAP
- My$99 Insulin Program (all Novo insulins, $99/month flat)
- Patient Assistance Program for uninsured/low-income
- Apply at novocare.com
Key insight: Even for Sanofi and Novo Nordisk insulins (affected by tariff), their manufacturer programs can make insulin affordable. These programs are NOT going away due to the tariff.
Is $35/Month Medicare Insulin Cap at Risk?
No. The $35/month cap is federal law (Inflation Reduction Act, 2022). The tariff does not override statutory caps. Medicare and Medicaid insulin pricing is protected.
However, the cap applies to the patient's cost-sharing, not the drug's list price. Insurers still pay the (now higher) wholesale price. This could pressure:
- Insurance premiums (modest increase)
- Part D plan structures
- Pharma company margins
Frequently Asked Questions
I'm a Type 1 diabetic — can I safely switch my insulin?
Often yes, but work with your doctor. Same-class substitutions (e.g., Lantus → Basaglar → Semglee, all insulin glargine) are typically straightforward. Cross-class changes (e.g., long-acting to intermediate) require more careful management.
What if I use an insulin pump?
Most insulin pumps are compatible with most rapid-acting insulins, but check your pump manufacturer's guidance. Humalog and NovoLog are both commonly used in pumps. Switching pump insulin is usually straightforward with doctor approval.
Can I get insulin from Canada cheaper?
The FDA has historically exercised discretion for personal importation of 90-day insulin supplies for personal use, but this is case-by-case. The Section 232 tariff applies at commercial ports of entry. Personal imports may be subject to CBP treatment at the border. Consult a licensed pharmacist before ordering.
What about compounded insulin?
Compounded insulin exists but is much less common than compounded GLP-1s. Most diabetes specialists discourage compounded insulin due to concentration precision requirements. Stick to FDA-approved options.
Will I need to change my blood sugar routines?
Possibly. When switching insulin brands or types, your glucose monitoring frequency should increase temporarily. Expect 2-4 weeks of closer monitoring after any switch.
Conclusion
For Medicare enrollees, the $35/month insulin cap fully protects you from tariff impact. For commercial insurance patients, expect modest copay increases on imported insulins (Lantus, NovoLog, Tresiba). For uninsured/cash patients, switching to US-made Lilly insulins (Humalog, Humulin, Basaglar) or biosimilars (Semglee, Rezvoglar) completely avoids the tariff impact. Don't let tariff news cause you to ration insulin — manufacturer programs guarantee access. Check your specific insulin's tariff status here.